GlassScriptPhysician profile
Mathew K George
NPI 1780866111
$4,114.99
in general payments reported to CMS, 2019-2025
21 companies · $890 in 2025
The $890 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $345 · 2021: $237 · 2022: $593 · 2023: $693 · 2024: $882 · 2025: $890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,465.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $869.88 | 2019-2025 | Tryptyr, Rocklatan, Centurion |
| Abbvie INC. | $680.50 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $424.20 | 2021-2025 | Acthar |
| Amgen INC. | $315.41 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $306.96 | 2024-2025 | |
| Sight Sciences, INC. | $304.07 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Allergan, INC. | $226.72 | 2020-2022 | |
| New World Medical,INC. | $189.25 | 2021-2025 | Streamline, Ahmed Glaucoma Valve, Clearpath |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $154.17 | 2019-2021 | |
| Harrow Eye, LLC | $128.85 | 2024-2025 | Vevye |
| Sun Pharmaceutical Industries INC. | $98.59 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $86.16 | 2020-2023 | |
| Bausch & Lomb Americas INC. | $75.24 | 2022-2025 | Miebo, Xiidra |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Aerie Pharmaceuticals, INC. | $52.63 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $44.98 | 2019-2022 | |
| Rxsight INC | $21.78 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Kala Pharmaceuticals, INC. | $19.99 | 2021 | |
| Shire North American Group INC | $17.51 | 2019 | |
| Glaukos Corporation | $17.15 | 2024 | Idose |
| Dompe US, INC. | $16.24 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathew George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.